$4.07
-0.10 (-2.40%)
USD · as of 2026-08-20 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where MGNX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
39 interventional · 2 expanded access · 18 with posted results
Held by 10 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, TWO SIGMA INVESTMENTS, LP, MILLENNIUM MANAGEMENT LLC, MARSHALL WACE, LLP, D. E. Shaw & Co., Inc., +5 more) · FINRA short interest 9.3 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study of MGC026 in Participants With Advanced Solid TumorsNCT06242470Number of participants with adverse events (AEs) and serious AEs (SAEs), AEs leading to dose delay, AEs leading to dose reduction, AEs leading to treatment discontinuations, AEs meeting criteria for dose limiting toxicity, and AEs of special interest.Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Biological: MGC026 Dose Escalation, MGC026 Dose for Expansion | Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer, Breast Cancer, Ovarian Cancer, Esophageal Squamous Cell Cancer (SCC) | 250 | May 2028 | ≤ 649 d | 2026-08-11 |
| A Study of Lorigerlimab in Participants With Advanced Solid TumorsNCT06730347Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as determined by the investigatorNon-randomized · Open-label · Treatment | Phase 2 | Recruiting | Biological: Lorigerlimab | Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Clear Cell Adenocarcinoma of Ovary, Clear Cell Adenocarcinoma of Vulva, Clear Cell Adenocarcinoma of Vagina, Clear Cell Adenocarcinoma of Cervix, Clear Cell Adenocarcinoma of Uterus, Clear Cell Adenocarcinoma of Fallopian Tube, Clear Cell Adenocarcinoma of Peritoneum, Endometrial Cancer | 80 | Jul 2027 | ≤ 344 d | 2026-06-02 |
| A Study of MGD024 in Patients With Relapsed or Refractory Hematologic MalignanciesNCT05362773Number of severe side effects in patients receiving MGD024Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: MGD024 | Leukemia, Acute Myeloid, Myelodysplastic Syndromes, Classical Hodgkin Lymphoma, Leukemia, B-cell, Leukemia, Hairy Cell, Mastocytosis, Aggressive Systemic, Blastic Plasmacytoid Dendritic Cell Neoplasm, Chronic Myeloid Leukemia | 130 | Nov 2026 | ≤ 101 d | 2026-07-28 |
| A Study of MGC028 in Participants With Advanced Solid TumorsNCT06723236Number and Types of Adverse Events (AEs) in Participants Receiving MGC028Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Biological: MGC028 | Advanced Solid Tumors, NSCLC Adenocarcinoma, Cholangiocarcinoma, Pancreatic Carcinoma, Colorectal Carcinoma | 124 | Nov 2026 | ≤ 101 d | 2026-04-27 |
| A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate CancerNCT05848011Median radiographic progression free survival (rPFS) determined by investigator review.Randomized · Open-label · Treatment | Phase 2 | Completed | Biological: lorigerlimab · Drug: docetaxel, Prednisone | Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent, Androgen-Insensitive Prostatic Cance, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Immunotherapy, Immune Checkpoint Inhibitor, Inhibitory Checkpoint Molecule | 154 | 2026-02-19actual | — | 2026-05-22 |
| A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid TumorsNCT05293496Number of participants with adverse events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Biological: vobramitamab duocarmazine, lorigerlimab | Advanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma, Pancreatic Ductal Carcinoma, Hepatocellular Cancer, Epithelial Ovarian Cancer, Renal Cell Carcinoma | 31 | 2025-06-24actual | — | 2025-10-14 |
| MGD019 DART® Protein in Unresectable/Metastatic CancerNCT03761017Incidence of treatment-emergent adverse eventsNon-randomized · Open-label · Treatment | Phase 1 | Completed | Biological: Lorigerlimab | Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic, Cutaneous Melanoma, Colorectal Cancer, Advanced Cancer, Solid Tumor, Adult | 162 | 2024-08-29actual | — | 2025-03-06 |
| A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid TumorsNCT05551117results2026-02-09Part 1: Six-month Radiographic Progression Free Survival (rPFS) as Determined by the InvestigatorRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Business reasons | Biological: vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine · Drug: Abiraterone, Enzalutamide | Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma | 192 | 2024-07-04actual | — | 2026-02-09 |
| A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral TherapyNCT05261191results2025-03-28Number and Types of Adverse Events (AEs), Including Serious Adverse Events (SAEs), and AEs Leading to Treatment Discontinuation in Participants Receiving MGD020 Alone in Part 1ANon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Biological: MGD020, MGD014 | Human Immunodeficiency Virus I Infection, Immunodeficiency Virus Type 1, Human, Human Immunodeficiency Virus Type 1 | 17 | 2024-05-29actual | — | 2025-03-28 |
| Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerNCT04082364results2025-04-22Number of Participants With Adverse Events of Margetuximab Plus Retifanlimab in Cohort A, as Assessed by CTCAE v5.0Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Completed | Biological: margetuximab, Retifanlimab, Tebotelimab, Trastuzumab · Other: Chemotherapy | Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer | 82 | 2024-01-15actual | — | 2025-06-08 |
| MGC018 With or Without MGA012 in Advanced Solid TumorsNCT03729596results2025-07-31Number of Patients With Adverse Events of Vobramitamab Duocarmazine as Assessed by CTCAE v4.03Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Business decision | Biological: vobramitamab duocarmazine | Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Melanoma, Advanced Solid Tumor, Adult, Metastatic Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer | 143 | 2023-03-18actual | — | 2025-07-31 |
| A Study of MGD013 in Patients With Unresectable or Metastatic NeoplasmsNCT03219268Number of participants with Treatment-Emergent Adverse Events (TEAE) as assessed by CTCAE v4.03 (tebotelimab monotherapy)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Biological: tebotelimab 1 mg, tebotelimab 3 mg, tebotelimab 10 mg, tebotelimab 30 mg, tebotelimab 120 mg, tebotelimab 300 mg, tebotelimab 400 mg, tebotelimab 600 mg, tebotelimab 800 mg, tebotelimab 1200 mg, margetuximab | Advanced Solid Tumors, Hematologic Neoplasms, Ovarian Cancer, HER2-positive Advanced Solid Tumors, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Cholangiocarcinoma, Cervical Cancer, TNBC - Triple-Negative Breast Cancer | 277 | 2023-02-08actual | — | 2023-12-21 |
| Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck CancerNCT04634825results2023-12-20Overall Response Rate (ORR) of Enoblituzumab Plus RetifanlimabNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Based on internal review of safety data | Biological: Enoblituzumab, Retifanlimab, Tebotelimab | Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma | 62 | 2022-07-29actual | — | 2023-12-20 |
| Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)NCT02152956results2024-01-30Efficacy Based on CR or CRh RateNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Business decision | Biological: Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off, Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off, Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off, Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off, Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose, Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose, Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose, Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose, Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose, Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose · Drug: Ruxolitinib | AML | 244 | 2022-07-05actual | — | 2024-01-30 |
| Safety Study of MGAH22 in HER2-positive CarcinomasNCT01148849Occurrence of Adverse Events and Serious Adverse EventsNon-randomized · Open-label · Treatment | Phase 1 | Completed | Biological: margetuximab | Breast Cancer, Gastric Cancer | 66 | 2022-06-14actual | — | 2025-02-26 |
| MGD009/MGA012 Combination in Relapsed/Refractory CancerNCT03406949Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.03Open-label · Treatment | Phase 1 | Completed | Biological: obrindatamab, retifanlimab | Advanced Solid Tumors | 25 | 2022-04-27actual | — | 2022-05-19 |
| MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral TherapyNCT03570918results2022-09-02Number of Participants With Treatment-Emerging Adverse EventsNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Biological: MGD014 | HIV-1-infection | 21 | 2021-09-28actual | — | 2022-09-02 |
| Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory CancerNCT02475213results2025-08-11Number of Participants With Dose-limiting Toxicities (DLT) After Administration of Enoblituzumab and Pembrolizumab or RetifanlimabNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Biological: Enoblituzumab Schedule 1, Pembrolizumab, Enoblituzumab Schedule 2, retifanlimab | Melanoma, Head and Neck Cancer, Non Small Cell Lung Cancer, Urothelial Carcinoma | 146 | 2021-08-18actual | — | 2025-08-11 |
| Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast CancerNCT02492711results2022-11-23Progression-free Survival (PFS) as Determined by Independent Radiological Review.Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Margetuximab, Trastuzumab · Drug: Physician's choice of chemotherapy. | HER-2 Positive Breast Cancer, Metastatic Neoplasm | 624 | 2021-08-11actual | — | 2025-03-17 |
| Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction CancerNCT02689284results2022-08-04Number of Patients With Dose Limiting ToxicitiesNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: Margetuximab 10 mg/kg, Margetuximab 15 mg, Pembrolizumab | Gastric Cancer, Stomach Cancer, Esophageal Cancer | 95 | Jan 2021actual | — | 2025-03-17 |
| Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and NeckNCT04129320Overall Response Rate (Modules X and Y)Non-randomized · Open-label · Treatment | Phase 2/3 | Withdrawnsponsor's stated reason: Change in study design | Biological: enoblituzumab, MGA012, MGD013 | Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck | 0 | Oct 2020 | — | 2022-02-08 |
| MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal CancerNCT03531632results2021-11-10Number of Participants With Adverse EventsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: MGD007 + MGA012 | Colorectal Cancer Metastatic | 38 | 2020-02-08actual | — | 2022-02-08 |
| Safety Study of MGD009 in B7-H3-expressing TumorsNCT02628535Number of participants with adverse eventsOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Business decision (not for safety reasons) | Biological: MGD009 | Mesothelioma, Bladder Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non Small Cell Lung Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Thyroid Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Colon Cancer, Soft Tissue Sarcoma | 67 | 2019-11-25actual | — | 2022-02-08 |
| Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid TumorsNCT02982941Safety and tolerability of enoblituzumab.Open-label · Treatment | Phase 1 | Completed | Drug: Enoblituzumab | Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Ewing Sarcoma, Wilms Tumor, Desmoplastic Small Round Cell Tumor | 25 | 2019-05-22actual | — | 2022-02-08 |
| Safety Study of MGA271 in Refractory CancerNCT01391143SafetyOpen-label · Treatment | Phase 1 | Completed | Biological: MGA271 | Prostate Cancer, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Head and Neck Cancer, Bladder Cancer, Non-small Cell Lung Cancer | 179 | 2019-04-18actual | — | 2022-02-08 |
| Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal CarcinomaNCT02248805Characterize dose limiting toxicity and establish a maximum tolerated dose and scheduleNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: MGD007 | Colorectal Carcinoma | 95 | 2018-07-02actual | — | 2022-02-08 |
| Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory CancerNCT02381314Number of participants with adverse eventsOpen-label · Treatment | Phase 1 | Completed | Biological: enoblituzumab plus ipilimumab | Melanoma, Non Small Cell Lung Cancer | 24 | 2017-11-09actual | — | 2022-02-08 |
| Phase 1 Study of MGD010 in Healthy SubjectsNCT02376036Safety and Tolerability as assessed by AEs and SAEsRandomized · Quadruple-masked · Basic science | Phase 1 | Completed | Drug: MGD010, Placebo · Biological: Hepatitis A vaccine | Healthy Subjects | 73 | Feb 2017actual | — | 2022-02-08 |
| Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast CancerNCT01828021results2020-09-17Best Overall ResponseOpen-label · Treatment | Phase 2 | Completed | Biological: Margetuximab | Breast Cancer | 25 | 2016-12-07actual | — | 2025-03-13 |
| Tissue Procurement Substudy for Participants in Study CP-MGA271-01NCT01918930Mechanism of ActionOpen-label · Basic science | Phase 1 | Terminatedsponsor's stated reason: Unable to accrue as planned for optional biopsies | Biological: MGA271 | Melanoma | 6 | Oct 2016actual | — | 2022-02-08 |
| Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes MellitusNCT00920582results2023-12-20Proportion of Subjects With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%.Randomized · Triple-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Business decision | Biological: Teplizumab Herold Regimen, Teplizumab 33.3% Herold Regimen, Teplizumab Curtailed Herold Regimen · Drug: Placebo | Type 1 Diabetes Mellitus | 254 | Apr 2012actual | — | 2023-12-20 |
| Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01)NCT00870818results2023-08-09The Number of Participants Who Experience an Adverse Event, Serious Adverse Event or Adverse Event of Special Interest.Non-randomized · Quadruple-masked · Other | Not applicable | Terminatedsponsor's stated reason: Business decision | Diagnostic test: Blood samples for safety, Analysis of T-cell subsets · Behavioral: Patient reported outcome questionnaires | Type 1 Diabetes Mellitus | 219 | Feb 2011actual | — | 2023-08-09 |
| Treatment of West Nile Virus With MGAWN1NCT00927953results2012-11-07The Number of West Nile Neuroinvasive Disease (WNND) Participants Who Show Improvement in the Modified Rankin Scale (MRS) (>=1 Improvement in Score)Randomized · Quadruple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Early termination due to the inability to enroll (13 of 120 subjects enrolled) | Biological: MGAWN1, Placebo - normal saline | West Nile Neuroinvasive Disease, West Nile Virus Infection, Encephalitis, Meningitis, Acute Flaccid Paralysis, West Nile Fever | 13 | Feb 2011actual | — | 2022-02-10 |
| Subcutaneous Administration of Teplizumab in Adults With Type 1 DiabetesNCT01189422Dose regimenRandomized · Quadruple-masked · Other | Phase 1 | Terminated | Drug: teplizumab or placebo | Type 1 Diabetes Mellitus | 1 | Feb 2011actual | — | 2022-02-08 |
| Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe PsoriasisNCT00954915results2012-04-19Adverse Events (AE)Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Injection site reaction met protocol-defined stopping criteria. | Biological: teplizumab | Psoriasis | 1 | Jul 2010actual | — | 2022-02-10 |
| The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes MellitusNCT00385697results2023-12-05Number of Subjects in Segment 2 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%.Randomized · Triple-masked · Treatment | Phase 2/3 | Completed | Biological: Teplizumab · Drug: Placebo | Type 1 Diabetes Mellitus | 554 | Jun 2010actual | — | 2023-12-05 |
| Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic CancerNCT00625586results2012-12-19Number of Patients Alive at 8 MonthsOpen-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Corporate decision | Biological: RAV12 · Drug: Gemcitabine | Pancreatic Cancer | 2 | 2009-01-21actual | — | 2023-11-03 |
| A Trial to Evaluate the Safety of a Single Intravenous Infusion of MGAWN1 in Healthy AdultsNCT00515385The incidence of adverse events and serious adverse events through the end of the study.Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: MGAWN1, MGAWN1 · Other: Placebo | West Nile Virus | 40 | Dec 2008actual | — | 2022-02-22 |
| RAV12 in Treating Patients With Metastatic or Recurrent AdenocarcinomaNCT00101972Toxicity by CTCAEOpen-label · Treatment | Phase 1 | Completed | Biological: monoclonal antibody RAV12 | Cancer | 53 | May 2008actual | — | 2022-02-22 |
| Expanded Access to MGAWN1 in Subjects With Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection; or Substantial Accidental ExposureNCT01206504expanded access | — | No longer available | Biological: MGAWN1 | West Nile Virus Infection | — | — | — | 2022-02-22 |
| Flotetuzumab Expanded Access ProgramNCT04678466expanded access | — | No longer available | Biological: flotetuzumab | Acute Myeloid Leukemia, AML, AML, Adult Recurrent | — | — | — | 2022-05-31 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19